Navigation Links
Data from Randomized Pilot Study, Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
Date:5/8/2008

Other Data Presentations to Focus on Use of Pro-Healing Stent with AMI

Patients and Those Who Cannot Tolerate Dual-Antiplatelet Therapy

HONG KONG, May 8 /PRNewswire/ -- Twelve-month follow-up data from both a randomized pilot study and the real-world registry use of OrbusNeich's Genous Bio-engineered R stent, the world's first pro-healing stent, will be presented next week in a symposium at EuroPCR 2008 in Barcelona, Spain.

The symposium, titled "Clinical Impact of the Pro-Healing Stent," will take place at noon on May 15. Germano Di Sciascio, M.D., professor and chairman of cardiology at Campus Biomedico, University of Rome, Italy, will serve as the chairperson of the symposium and will present 14 month follow up data on 78 patients treated with the Genous stent.

Jonathan Hill, M.D., of King's College, London, will discuss the functional importance of endothelial progenitor cells for accelerated natural healing. Huay-Cheem Tan, M.D., National University Hospital, Singapore will present on the use of the Genous Bio-engineered R stent in acute myocardial infarction patients and Michael Kutryk, M.D., Ph.D. of St. Michael's Hospital, Toronto will focus on the use of the stent in patients who cannot tolerate dual-antiplatelet therapy.

Robbert de Winter, M.D., Ph.D., director of the catheterization laboratory at the Academic Medical Center, Amsterdam, will show the 12 month follow-up data from a 193-patient, single-center, prospective, single blind study called TRIAS HR Pilot with the Genous stent randomized with a drug eluting stent. In addition, de Winter will include interim follow up data from patient subsets in e-HEALING, a monitored, multi-center, worldwide (outside the United States) prospective registry with 5,000 enrolled patients. Dr de Winter is the principal investigator of the TRIAS HR Pilot study and co-principal investigator of the e-HEALING registry.

"We expect the data to strengthen our conviction that Gen
'/>"/>

SOURCE OrbusNeich
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
2. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
3. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
4. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
5. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
6. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
7. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
8. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
9. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
10. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
11. Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Calif., Dec. 14 The Roberts ... today released the analysis of social responsibility ... world-wide. The report contains a compilation of ... environmental and social reporting of the companies. ... and performance for both environmental and social ...
(Date:12/14/2009)... According to Millennium Research Group (MRG), the global ... of safety devices for small-bore connectors for disposable ... of the enteral feeding device markets in both ... and European Markets for Enteral Feeding Devices 2010 ... will experience the greatest impact from facilities switching ...
(Date:12/14/2009)... Inc. (Nasdaq: MYL ) today announced that ... Index Dec. 21. Mylan,s common shares will also ... Chairman and CEO Robert J. Coury said: "We ... followed index of leading companies. This development marks ... the rapid growth and strong potential of our ...
Breaking Medicine Technology:New Report Grades Sustainability Reporting of Top Pharmaceutical Companies 2New Report Grades Sustainability Reporting of Top Pharmaceutical Companies 3Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3Mylan Added to NASDAQ-100 Index 2ECI Hires Robin Raff as Director of Strategy 55780 1ECI Hires Robin Raff as Director of Strategy 55780 2Lets Get it Done 21 From Coast to Coast USAction Affiliates Rally This Week for Quality Affordable Health Care 55777 1Lets Get it Done 21 From Coast to Coast USAction Affiliates Rally This Week for Quality Affordable Health Care 55777 2Cost Effective Solution for Patient Testing 3A Introducing Comprehensive and Affordable Molecular Diagnosis With Verifiable Accuracy 55774 1Cost Effective Solution for Patient Testing 3A Introducing Comprehensive and Affordable Molecular Diagnosis With Verifiable Accuracy 55774 2
... Tamoxifen in,a Single Trial , LUTON, UK, ... of a single trial has demonstrated that survival ... switching from,tamoxifen to anastrozole (Arimidex). An analysis of ... The,Journal of Clinical Oncology, confirms that postmenopausal women,who ...
... WIRE)--Jun 18, 2007 - Salix,Pharmaceuticals, Ltd. (NASDAQ:SLXP) ... its Phase III registration trial to,evaluate the ... mg tablet,formulation of balsalazide disodium (balsalazide tablets).,Balsalazide ... 750 mg, an anti-inflammatory drug approved and ...
Other Medicine Technology:Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal,Women with Early Breast Cancer Receiving Treatment with Tamoxifen 2Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal,Women with Early Breast Cancer Receiving Treatment with Tamoxifen 3Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal,Women with Early Breast Cancer Receiving Treatment with Tamoxifen 4Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal,Women with Early Breast Cancer Receiving Treatment with Tamoxifen 5Salix Pharmaceuticals Announces Positive Top Line Results of,Balsalazide Tablets Registration Study 2Salix Pharmaceuticals Announces Positive Top Line Results of,Balsalazide Tablets Registration Study 3
(Date:12/14/2009)... Americold Realty Trust ("Americold") announced today that it has ... U.S. Securities and Exchange Commission (the "SEC") relating to ... The number of shares to be offered and the ... determined. The common shares to be sold in this ... ,, The joint book-running managers of the offering will ...
(Date:12/14/2009)... CITY, Calif., Dec. 14 United Dental Care ... one of the providers of top-notch dental care in ... dentistry, restorative dentistry, kid,s dentistry, braces (orthodontics) and periodontal ... Los Angeles Dentist offices are staffed with experienced ... ,, Dr. Eftekhari (Dr. E) is one ...
(Date:12/14/2009)... ... La Jolla, Calif. (Vocus) -- The physicians at Scripps ... new chief of staff of the 372-bed facility. Dr. Sedwitz will ... 1, 2010. , , , , ,During his two-year term, Dr. ... administrative staff and its board of directors. Dr. Sedwitz will play ...
(Date:12/14/2009)... ANA, Calif., Dec. 14 Grubb & Ellis Healthcare ... has authorized a daily distribution to stockholders of record as ... period commencing on Jan. 1, 2010 and ending on Feb. ... 365 days in the calendar year and will be equal ... purchase price of $10.00 per share. These distributions will ...
(Date:12/14/2009)... An estimated 29,000 future cancers could be linked to scans ... -- Commonly performed CT scans are exposing patients to far ... cause tens of thousands of cancers a year, two new ... Dec. 14/28 issue of the Archives of Internal Medicine ... Dr. Rita F. Redberg, are calling on clinicians to limit ...
Breaking Medicine News(10 mins):Health News:Americold Realty Trust Files Registration Statement for Proposed Initial Public Offering 2Health News:United Dental Care, Gentle Care, Trusted Dentists 2Health News:United Dental Care, Gentle Care, Trusted Dentists 3Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 2Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 3Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 2Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 3Health News:Studies Quantify Cancer Risks From CT Scans 2Health News:Studies Quantify Cancer Risks From CT Scans 3Health News:Studies Quantify Cancer Risks From CT Scans 4
... Nihat Kabi said that the country was preparing itself to ... the bird flu infection (H5N1 strain) in Turkey. // ... flu centres if it emerges. Of 31 cases in Romania, ... northeast Bulgarian town of Silistra", told in a television interview. ...
... The deaths of three people, two of them in Escondido, ... prompting a new look at smoking safety. ,Wheelchair-bound Edward ... the Palomar Heights Care Center in Escondido. There are conflicting ... exploded or not. ,On Tuesday, Marsha Duran (55) ...
... Roman Catholic priests in Tulua, a Colombian town, are up in ... older must carry a condom at all times to reduce unwanted ... has said he would be presenting a formal proposal requiring all ... the town — to carry at least one condom. Those caught ...
... (IADR) has decided to confer the H. ... to Professor Anthony Blinkhorn of the School ... // ,Professor Blinkhorn has made a ... health and was even awarded an OBE ...
... the UK are turning to smoking and alcohol to overcome ... automated call centers, //according to a recent study. The study ... ,The DPP conducted a poll of 1,000 people ... a major source of stress and 27% of the men ...
... A Chinese company will commence exports of live hepatitis A ... clearance to do so. ,The export by the ... vaccines.// The vaccine, developed by Chinese scientists, has been tried ... effective in bringing down incident rates of the disease by ...
Other Medicine News:Health News:Spate of smoking-related fire deaths cause concern in San Diego 2Health News:More Britons Take To Alcohol Because Of Stress 2
The NexGen CR femoral component is intended for patients who, in the physician's judgement, have good bone stock and whose ligaments provide adequate mediolateral, anteroposterior, and varus/valgus s...
... Genesis II* Total Knee System will define ... more is possible with less - reducing ... fully addressing both clinical and cost situations. ... these design goals, giving surgeons creative solutions ...
Cruciate retaining, posterior stabilized and constrained components....
The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results....
Medicine Products: